MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2021.12.024

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2022

Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.

Drobni Zsofia D, Michielin Olivier, Quinaglia Thiago, Zlotoff Daniel A, Zubiri Leyre, Gilman Hannah K, Supraja Sama, Merkely Bela, Muller Veronika, Sullivan Ryan J, Reynolds Kerry L, Pittet Michael J, Jain Rakesh K, Neilan Tomas G

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Preclinical studies indicate that the concurrent use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) may improve outcomes in broad groups of patients with cancer. There are limited data on the association between the use of RAAS inhibitors and outcomes among patients treated with immune checkpoint inhibitors (ICIs).

METHODS

We performed a retrospective study of all patients treated with an ICI in a single academic network. Of 10,903 patients, 5910 were on any anti-hypertensive medication. Of those on anti-hypertensive therapy, 3426 were prescribed a RAAS inhibitor during ICI treatment, and 2484 were prescribed other anti-hypertensive medications. The primary outcome was overall survival in the entire cohort and in sub-groups by cancer types.

RESULTS

Thoracic cancer (34%) and melanoma (16%) were the most common types of cancer. Those prescribed a RAAS inhibitor were older, more frequently male, and had more cardiovascular risk factors. In a Cox proportional hazard model, the concurrent use of RAAS inhibitors was associated with better overall survival (hazard ratio (HR):0.92, [95% Confidence Interval (CI):0.85-0.99], P = .032). Patients with gastrointestinal (HR:0.82, [95% CI: 0.67-1.01], P = .057) and genitourinary cancer (HR:0.81, [95% CI:0.64-1.01], P = .067) had a non-statistically significant better overall survival.

CONCLUSIONS

In this large retrospective study, patients with hypertension who were concomitantly taking a RAAS inhibitor during ICI therapy had better overall survival. This benefit was primarily noted among patients with gastrointestinal and genitourinary cancers. Prospective randomized trials are warranted to further evaluate and specify the benefit of RAAS inhibitors in patients with cancer who receive ICI therapy.

Для цитирования: Drobni Zsofia D, Michielin Olivier, Quinaglia Thiago, Zlotoff Daniel A, Zubiri Leyre, Gilman Hannah K, Supraja Sama, Merkely Bela, Muller Veronika, Sullivan Ryan J, Reynolds Kerry L, Pittet Michael J, Jain Rakesh K, Neilan Tomas G. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.. European journal of cancer (Oxford, England : 1990). 2022. DOI: 10.1016/j.ejca.2021.12.024.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.